Keytruda (pembrolizumab)

pCPA File Number: 21671
Negotiation Status:
Under consideration for negotiation
Indication(s):
First-line treatment of locally advanced unresectable or metastatic, carcinoma of the esophagus or HER-2 negative gastroesophageal junction adenocarcinoma in combination with platinum and fluoropyrimidine based chemotherapy, in adult patients
Sponsor/Manufacturer:
Merck Canada Inc.
CADTH Project Number:
PC0250
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable